Delparantag is a novel, salicylamide-derived, small molecule. Delparantag is heptagonist. It acts as universal anticoagulation-reversing agent. Delparantag neutralized the antithrombotic, anticoagulant, and bleeding effects of heparins as effectively as protamine sulfate and may be slightly more efficacious against low-molecular-weight heparins (LMWHs). This agent was designed to restore coagulation by specifically binding to the pentasaccharide and disrupting unfractionated heparin and LMWH interaction with antithrombin. Delparantag has been shown to completely reverse the anticoagulant effects of heparin and normalize blood-clotting time in six human subjects in less than 10 minutes in a phase IB clinical trial. In clinical trial studies, safety was ascertained by blood pressure measurements and efficacy was determined by measuring blood clotting time (aPTT, Activated Partial Thromboplastin Time, or ACT, Activated Coagulation Time). Plasma half-life elimination of delparantag is between 3 and 5 min. Development was recently paused due to hypotension noted in the studies although this may be avoided with longer administration times and will require further investigation.